Abstract:The persistence of increased excitability and spontaneous activity in injured peripheral neurons is imperative for the development and persistence of many forms of neuropathic pain. This aberrant activity involves increased activity and/or expression of voltage-gated Na + and Ca 2+ channels and hyperpolarization activated cyclic nucleotide gated (HCN) channels as well as decreased function of K + channels. Because they display limited central side effects, peripherally restricted Na + and Ca 2+ channel blockers and K + channel activators offer potential therapeutic approaches to pain management. This review outlines the current status and future therapeutic promise of peripherally acting channel modulators. Selective blockers of Na v 1.3, Na v 1.7, Na v 1.8, Ca v 3.2, and HCN2 and activators of K v 7.2 abrogate signs of neuropathic pain in animal models. Unfortunately, their performance in the clinic has been disappointing; some substances fail to meet therapeutic end points whereas others produce dose-limiting side effects. Despite this, peripheral voltage-gated cation channels retain their promise as therapeutic targets. The way forward may include (i) further structural refinement of K + channel activators such as retigabine and ASP0819 to improve selectivity and limit toxicity; use or modification of Na + channel blockers such as vixotrigine, PF-05089771, A803467, PF-01247324, VX-150 or arachnid toxins such as Tap1a; the use of Ca 2+ channel blockers such as TTA-P2, TTA-A2, Z 944, ACT709478, and CNCB-2; (ii) improving methods for assessing “pain” as opposed to nociception in rodent models; (iii) recognizing sex differences in pain etiology; (iv) tailoring of therapeutic approaches to meet the symptoms and etiology of pain in individual patients via quantitative sensory testing and other personalized medicine approaches; (v) targeting genetic and biochemical mechanisms controlling channel expression using anti-NGF antibodies such as tanezumab or re-purposed drugs such as vorinostat, a histone methyltransferase inhibitor used in the management of T-cell lymphoma, or cercosporamide a MNK 1/2 inhibitor used in treatment of rheumatoid arthritis; (vi) combination therapy using drugs that are selective for different channel types or regulatory processes; (vii) directing preclinical validation work toward the use of human or human-derived tissue samples; and (viii) application of molecular biological approaches such as clustered regularly interspaced short palindromic repeats (CRISPR) technology.

Reversal of experimental neuropathic pain by T-type calcium channel blockers

Increased expression of Ca3.2 T-type calcium channels in damaged DRG neurons contributes to neuropathic pain in rats with spared nerve injury.

Suppression of Inflammatory and Neuropathic Pain by Uncoupling CRMP-2 from the Presynaptic Ca2+ Channel Complex

Alleviation of neuropathic pain by regulating T-type calcium channels in rat anterior cingulate cortex

Upregulation of Cav3.2 T-type Calcium Channels in Adjacent Intact L4 Dorsal Root Ganglion Neurons in Neuropathic Pain Rats with L5 Spinal Nerve Ligation

Involvement of N-type Calcium Channels in Pain and Antinociception

Inhibition of NF-kappaB Prevents Mechanical Allodynia Induced by Spinal Ventral Root Transection and Suppresses the Re-Expression of Nav1.3 in DRG Neurons in Vivo and in Vitro.

Accumulation of Cav3.2 T-type Calcium Channels in the Uninjured Sural Nerve Contributes to Neuropathic Pain in Rats with Spared Nerve Injury.

Peripheral Voltage-Gated Cation Channels in Neuropathic Pain and Their Potential as Therapeutic Targets

Involvement of NF-κB and the CX3CR1 Signaling Network in Mechanical Allodynia Induced by Tetanic Sciatic Stimulation

Brain-derived Neurotrophic Factor Stimulation of T-type Ca 2+ Channels in Sensory Neurons Contributes to Increased Peripheral Pain Sensitivity

Neuromedin B Receptor Stimulation Of Cav3.2 T-Type Ca2+ Channels In Primary Sensory Neurons Mediates Peripheral Pain Hypersensitivity

Enhanced evoked excitatory transmitter release in experimental neuropathy requires descending facilitation

T-type calcium channels participate in intrinsic and synaptic activity of PKCγ neurons of the dorsal horn of the spinal cord during chronic pain

Upregulation of N-type Calcium Channels in the Soma of Uninjured Dorsal Root Ganglion Neurons Contributes to Neuropathic Pain by Increasing Neuronal Excitability Following Peripheral Nerve Injury.

Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain

Contribution of afferent pathways to nerve injury-induced spontaneous pain and evoked hypersensitivity

Neuromedin B receptor stimulation of Cav3.2 T-type Ca 2+ channels in primary sensory neurons mediates peripheral pain hypersensitivity

Nerve Injury Elevates Functional Cav3.2 Channels in Superficial Spinal Dorsal Horn.

Involvement of interaction of Cav3.2 and nociceptive TRPA1 in pathological pain transmission

Axonal accumulation of hyperpolarization-activated cyclic nucleotide-gated cation channels contributes to mechanical allodynia after peripheral nerve injury in rat.